UA109736C2 - POLYMORPH FORM OF MESILATE SALT 2- (2,4,5-SUBSTITUTED ANILINO) PYRIMIDINE (OPTIONS) - Google Patents

POLYMORPH FORM OF MESILATE SALT 2- (2,4,5-SUBSTITUTED ANILINO) PYRIMIDINE (OPTIONS)

Info

Publication number
UA109736C2
UA109736C2 UAA201403622A UAA201403622A UA109736C2 UA 109736 C2 UA109736 C2 UA 109736C2 UA A201403622 A UAA201403622 A UA A201403622A UA A201403622 A UAA201403622 A UA A201403622A UA 109736 C2 UA109736 C2 UA 109736C2
Authority
UA
Ukraine
Prior art keywords
compounds
salts
mutant
pyrimidine
substituted anilino
Prior art date
Application number
UAA201403622A
Other languages
Russian (ru)
Ukrainian (uk)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of UA109736C2 publication Critical patent/UA109736C2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Заявлений винахід стосується певних 2-(2,4,5-заміщених аніліно)піримідинових сполук та їх фармацевтично прийнятних солей, які можуть бути корисними в лікуванні або попередженні хвороби або медичного стану, опосередкованого через певні мутантні форми рецептора фактора росту епідермісу (наприклад, як-то активувальний мутант L858R, мутант делеції Ехоn19 та резистентний мутант Т790М). Такі сполуки та їх солі можуть бути корисними в лікуванні або попередженні різних раків.Винахід також стосується фармацевтичних композицій, які містять названі сполуки та їх солі, зокрема, придатних поліморфних форм цих сполук та солей, проміжної сполуки, придатної для виготовлення названих сполук, та способів лікування хвороб, опосередкованих різними відмінними формами EGFR, застосовуючи названі сполуки та їх солі.The claimed invention relates to certain 2- (2,4,5-substituted anilino) pyrimidine compounds and their pharmaceutically acceptable salts, which may be useful in the treatment or prevention of a disease or medical condition mediated through certain mutant forms of the epidermal growth factor receptor (eg, as is the L858R activation mutant, the Echon19 deletion mutant and the T790M resistant mutant). The following compounds and their salts may be useful in treating or preventing various cancers. The invention also relates to pharmaceutical compositions containing said compounds and their salts, in particular suitable polymorphic forms of these compounds and salts, an intermediate suitable for the manufacture of said compounds, and methods the treatment of diseases mediated by various different forms of EGFR, using the named compounds and their salts.

UAA201403622A 2011-07-27 2012-07-25 POLYMORPH FORM OF MESILATE SALT 2- (2,4,5-SUBSTITUTED ANILINO) PYRIMIDINE (OPTIONS) UA109736C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161512061P 2011-07-27 2011-07-27

Publications (1)

Publication Number Publication Date
UA109736C2 true UA109736C2 (en) 2015-09-25

Family

ID=53675818

Family Applications (3)

Application Number Title Priority Date Filing Date
UAA201312949A UA106710C2 (en) 2011-07-27 2012-07-25 COMPOUND 2- (2,4,5-substituted ANILINO) PIRIMIDINE AND ITS APPLICATION FOR CANCER TREATMENT
UAA201403622A UA109736C2 (en) 2011-07-27 2012-07-25 POLYMORPH FORM OF MESILATE SALT 2- (2,4,5-SUBSTITUTED ANILINO) PYRIMIDINE (OPTIONS)
UAA201403623A UA108954C2 (en) 2011-07-27 2012-07-25 Compounds 2- (2,4,5-substituted aniline) pyrimidine

Family Applications Before (1)

Application Number Title Priority Date Filing Date
UAA201312949A UA106710C2 (en) 2011-07-27 2012-07-25 COMPOUND 2- (2,4,5-substituted ANILINO) PIRIMIDINE AND ITS APPLICATION FOR CANCER TREATMENT

Family Applications After (1)

Application Number Title Priority Date Filing Date
UAA201403623A UA108954C2 (en) 2011-07-27 2012-07-25 Compounds 2- (2,4,5-substituted aniline) pyrimidine

Country Status (2)

Country Link
AR (1) AR115019A2 (en)
UA (3) UA106710C2 (en)

Also Published As

Publication number Publication date
AR115019A2 (en) 2020-11-18
UA108954C2 (en) 2015-06-25
UA106710C2 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
PH12015501326A1 (en) 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer
EA201590345A1 (en) METHODS OF CANCER TREATMENT USING 3- (4 - ((4- (MORFOLINOMETHYL) BENZYL) OXY) -1-OXIOIZINDOLIN-2-IL) PIPERIDIN-2,6-DIONA
EA201590624A1 (en) CYCLIC ETHERS OF PYRAZOL-4-IL-HETEROCYCLIL-CARBOXAMIDE COMPOUNDS AND METHODS OF THEIR APPLICATION
MX351305B (en) Mineralocorticoid receptor antagonists.
EA201500298A1 (en) ALCOXYPHAZOLES AS ACTIVATORS OF SOLUBLE GUANYLATZYCLASES
MY186126A (en) Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
EA201290957A1 (en) PYRAZOL-4-ILHETEROCYCLILKARBOXAMIDE COMPOUNDS AND METHODS OF THEIR APPLICATION
EA201391319A1 (en) CANCER TREATMENT METHOD USING 3- (5-AMINO-2-METHYL-4-OXO-4H-HINAZOLIN-3-IL) PIPERIDIN-2,6-DIONA
EA201291220A1 (en) AMINOPYRIMIDINE DERIVATIVES AS MODULATORS LRRK2
MX2014000536A (en) 4 - piperidinyl compounds for use as tankyrase inhibitors.
EA201370166A1 (en) CONTAINING DIRYLACETHYLENEHYDRAZIDE THYROZINKINASE INHIBITORS
EA201300250A1 (en) OXADIAZOL INHIBITORS OF LEUKOTRIEN PRODUCTION
EA201790246A1 (en) HETEROCYCLIC CARBONIC ACIDS AS ACTIVATORS OF SOLUBLE GUANYLATZYCLIC
UA104489C2 (en) Compounds for the treatment of dyslipidemia and related diseases
MX2012013206A (en) Fused bicyclic kinase inhibitors.
MX353209B (en) D2 ANTAGONISTS, METHODS OF SYNTHESIS and METHODS OF USE.
NZ706591A (en) Oxazolidin-2-one-pyrimidine derivatives
PH12020550228A1 (en) Epidermal growth factor receptor inhibitors
PH12014501943A1 (en) Novel compounds for the treatment of dyslipidemia and related diseases
UA109736C2 (en) POLYMORPH FORM OF MESILATE SALT 2- (2,4,5-SUBSTITUTED ANILINO) PYRIMIDINE (OPTIONS)
EA202092034A3 (en) 2- (2,4,5-SUBSTITUTED ANILINO) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR CANCER TREATMENT
NZ621471A (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
TN2013000052A1 (en) Oxadiazole inhibitors of leukotriene production
UY33283A (en) DERIVATIVES OF 2,3-DIHIDRO-1H-INDEN-1-IL-2,7-DIAZASPIRO [3.5] NONANO